Abstract: Exemplary embodiments described and shown herein generally relate to apparatus for detecting the level of carbon monoxide (CO) present in a passenger vehicle. Some embodiments may interface with standard 12 volt vehicle power outlets or with USB power outlets, while others may be designed to be hard-wired into a vehicle electrical system. An audible alarm, warning light, and/or display may be used to warn a passenger that CO levels are concerning or dangerous. In some embodiments, an engine kill switch may be included and activated when certain CO levels are detected from some period of time. Threat levels and corresponding time thresholds may be stored and used to determine when a warning should be issued.

Abstract: A long term portable gas detecting and monitoring apparatus includes a case having a continuous sidewall including a first end closed by a first end cap, and a second end closed by a second end cap connected sealably and removably to the continuous sidewall. The continuous sidewall is triangular between the closed end and the open having three sides and three corners, two of the three sides being straight and equal in length, one of the three sides being rounded, and each of the three corners being rounded. A long term gas detection and monitoring unit mounted in the case includes gas, and temperature and humidity sensors in communication with an ambient atmosphere outside the case, a data processor operatively connected to the sensors, data storage, an information display viewable through the case, and a calibration unit for calibrating the gas sensor to a predetermined gas concentration measured by the gas sensors.

Abstract: A compact explosive detecting system collects explosive residues in the form of vapor powder. The residues are accumulated on a desorber which is subjected to pyrolysis to release a gaseous sample. The sample is pumped to a detecting system through a metering valve. A luminol cell reacts with the gaseous sample to create chemiluminescence, the light output of which is measured by a photo multiplier tube. The light intensity is indicative of the amount of explosive present. Based on the amount of explosive present, a metering valve is adjusted to pass the gaseous sample into a highly sensitive metal oxide sensor array to detect NO2 from nitrogen containing explosive and CO/CO2 from non nitrogen containing explosive. The metal oxide sensor array reliably selects explosives from those compounds indicating chemiluminescence.

Abstract: A metal oxide heterostructure includes mixing a first precursor and a second precursor to form a precursor aqueous mixture, adding at least one constituent to the precursor aqueous mixture to form a first solution, adding a nanostructuring reagent to the first solution to form a second solution, sonochemically treating the second solution to provide a metal oxide powder, filtering, washing, and drying the metal oxide powder to provide a metal oxide nanocomposite heterostructure for a sensing layer of a hydrogen sulfide sensor. A method for forming a hydrogen sulfide sensor includes the metal oxide heterostructure, forming a sensing material, contacting the sensing material with interdigitated electrodes to form a sensing layer, and thermally consolidating the sensing layer to form the hydrogen sulfide sensor.

Abstract: The present disclosure provides for an electronic sensor for detecting a root of a plant in soil, the electronic sensor that includes a first conductor plate configured to be disposed in soil, a switch, a power supply, and signal extractor. The switch is electrically coupled to the first conductor plate and is configured to switch between a first mode and a second mode. The power supply is electrically coupled to the switch and is configured to provide an electrical charge to the first conductor plate in the first mode of the switch. The signal extractor is electrically coupled to the switch and is configured to extract a signal response at the first conductor plate in the second mode of the switch. The present disclosure further provides a second conductor plate configured to be disposed in soil adjacent to and substantially parallel to the first conductor plate. The second conductor plate is electrically coupled to ground.

Abstract: Electronic systems, devices and methods are provided to accurately record and analyze food intake and physical activity in a subject. A device is provided to be placed on a subject which records video using at least two video cameras positioned to record stereoscopic image pair, as well as other physiological and/or environmental data including, for example, oxygen saturation, heart rate, and environmental factors such as physical location, temperature, and humidity. Video data is analyzed along with other data obtained by the device to determine food consumption and/or physical activity of the subject, much of which is accomplished by automated computer-implemented processes.

Abstract: The present invention is a method for the early detection or prediction of souring of aqueous systems by detecting a population of lipid and organic acids and the treatment of such systems.

Abstract: Methods are provided for predicting the properties of an asphalt emulsion, such as an asphalt emulsion that contains an asphalt fraction derived from a plurality of crude oils. Corresponding tools are provided to allow for visualization of the predicted asphalt emulsion properties. The properties of the asphalt components in an asphalt fraction for forming an emulsion can be represented based on using a simplified functional form to represent each emulsion property of each asphalt component. The emulsion properties of an asphalt fraction, composed of a plurality of asphalt components, can be modeled based on a linear combination of the emulsion properties of the asphalt components.

Abstract: A health meter has a decontamination device for dirty fluid with a metal casing with metal lid, inlet port and outlet port, an open bucket having a docking lid and a plurality of openings, a hollow tube with an opening, a central hollow rod with rod opening connected to an outlet port, a convex reinforcing spacer in the open bucket, a compressible decontamination media and a reinforcing seat in the open bucket. Dirty fluid flows into the metal casing between the open bucket and metal casing through openings in the docking lid into the compressible decontamination media sequentially into the hollow tube and then into the central hollow rod and out the outlet port while an outlet sensor and an inlet sensor communicate with a controller in communication with a network and a plurality of client devices for automatic remote monitoring.

Abstract: A system includes a gas turbine system that combusts a fuel to produce a power, and the gas turbine system is disposed in a gas turbine site. The system also includes an analyzer system that determines multiple batch fuel characteristics of a batch of the fuel, and the batch of the fuel is delivered via a transport system. Moreover, the system includes a small batch fuel processing system that receives the batch of fuel and filters the batch of fuel to a filtered batch of fuel based on the multiple fuel characteristics. Further, the filtered batch of fuel adheres to manufacturer fuel recommended characteristics for use in the gas turbine system.

Abstract: Methods, systems, and apparatus to diagnose lubrication oil deterioration. In one aspect, a method includes irradiating a lubrication oil sample with a light beam to emit a light-induced fluorescence, detecting and processing the light-induced fluorescence signal to determine a temporal variation of a fluorescence intensity, identifying a steady state of the light-induced fluorescence signal, processing the temporal variation of the fluorescence intensity to determine a lubrication oil parameter, and correlating the oil parameter to a calibration curve to diagnose the lubrication oil deterioration.

Abstract: Systems and methods employ a test sensor that includes an identification feature, such as a resistive element or other detectable circuit element, which allows a measurement device to interrogate the test sensor and to determine whether the correct test sensor type is being used to collect a fluid sample. For example, some embodiments employ test sensors that a measurement device can identify according to a response received from the test sensors when the measurement device applies an electrical signal to the test sensors. By facilitating identification of a test sensor, embodiments help ensure that the desired test type, calibration codes, and/or assay sequence are applied to the fluid sample collected by the test sensor.

Abstract: A method of analyzing a wet blood sample is disclosed. The method includes dispensing a wet blood sample onto a substrate. The method also includes spotting a zinc sulfate solution onto the wet blood sample to fix or set the wet blood sample in place on the substrate, thereby trapping blood components inside the blood spot. The method further includes generating ions of an analyte in the wet blood sample and analyzing the ions.

Abstract: An objective biomarker is capable of evaluating the severity of depression and is clinically useful. The biomarker is used for evaluating the severity of depression, and includes at least one compound selected from the group made of 4-aminobutyric acid (? (gamma)-aminobutyric acid: GABA), arginine, argininosuccinate, isoleucine, indole carboxaldehyde, potassium indoleacetate, carnitine, acetylcarnitine, ornithine, xanthurenate, kynurenate, kynurenine, citrate, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyrate, phenylalanine, proline, betaine, and lysine.

Abstract: A method for analyzing a biologic fluid sample includes the steps of: a) providing a spatially mapped chamber; b) providing a predetermined repeatable non-uniform spatial distribution of one or more constituents within the sample, which distribution indicates the presence or absence of a statistically significant number of constituents within the sample in each chamber sub-region; c) selecting one or more image techniques for each sub-region based on the presence or absence of the statistically significant number of one or more constituents in that sub-region as indicated by the distribution; d) creating image data representative of the biologic fluid sample in each sub-region, using the one or more image techniques selected for that sub-region; and e) analyzing the sample.

Abstract: An imaging system for a rotatable object includes an imaging unit configured to take a series of images of a portion of the rotatable object and a light source. The light source is directed at the rotatable object and is configured to generate pulses of light that illuminate the rotatable object during rotation of the rotatable object and allow the imaging unit to take the series of images of the rotatable object. The system also includes a synchronizer that monitors the rotational position of the rotatable object as it rotates, and a controller in communication with the imaging unit, the light source, and the synchronizer. The controller controls the operation of the imaging unit and/or the light source based upon the rotational position of the rotatable object such that each of the series of images is taken at the same rotational position of the rotatable object.

Abstract: A method of verifying test data generated by a meter includes testing the sample with the meter. The meter further generates and displays a first analyte level, and calculates and displays a First Verification Value. The method further includes displaying a user interface using a computing system for receiving a user input and receiving the user input including the first analyte level and the First Verification Value. The receiving computing system calculates a Second Verification Value from the entered Result Data. The method further includes verifying with the computing system that the user input was correctly entered by comparing the entered First Verification Value with the calculated Second Verification Value and provides an indication to the user as to whether the user input was correctly entered. The meter may additionally generate additional analyte levels and the Verification Values include the additional analyte levels times corresponding, predetermined multipliers.

Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

Abstract: The urine analyzer 10 includes a sample preparation unit 30 for mixing a urine sample with a hemolytic agent to prepare a measurement sample, a flow cell 41 for flowing a measurement sample, a light source 42 for irradiating light on the measurement sample flowing through the flow cell 41, a light receiving unit 50 for receiving scattered light given off from the measurement sample by irradiation of light and outputting a scattered light signal, and an analysis unit 12 for detecting fat particles in the measurement sample by using a parameter reflecting the intensity of the scattered light signal output by the light receiving unit 50, and a parameter reflecting the width of the scattered light signal.

Abstract: A device for detecting a biomarker for inflammation in a respiratory system includes a sample collection and/or holding area to receive an exhaled breath condensate (EBC) sample obtained from a respiratory system; an electrode system coupled to the sample collection area, the electrode system including reduced graphene oxide (rGO); and circuitry coupled to the electrode system. The circuitry is configured to apply a voltage to the EBC sample in the sample collection area via the electrode system and to measure a current via the electrode system in response to the voltage applied, in order to determine a concentration of nitrite in the EBC sample based on the current measured. The concentration of nitrite is a biomarker for inflammation in the respiratory system.

Abstract: Disclosed are methods and compositions for identifying and treating certain conditions and diseases. In certain instances, the general inventive concepts provide methods for determining rhTRAIL sensitivity of a sample and/or methods and compositions for inducing apoptosis to treat conditions and diseases with rhTRAIL.

Abstract: An apparatus useful for examining metastasis of cancer cells, includes (a) a primary chamber; (b) at least one secondary chamber; (c) at least one primary conduit connecting said primary and secondary chambers and providing fluid communication therebetween; (d) a primary organoid in said first chamber, said primary organoid comprising mammalian cancer cells; (e) at least one secondary organoid separately selected for and in said secondary chamber(s); and (f) optionally a growth media in said primary chamber, each of said secondary chamber(s), and said primary conduit. The apparatus may be used in methods of drug screening and development, and in personalized medicine.

Abstract: A method for predicting an effect of a medication or a treatment regimen to a subject suffering from a cancer, the method comprises: (A) obtaining a tissue from the subject; (B) dissociating the tissue to obtain a multicellular cluster, wherein the multicellular cluster comprises the cancer cell; (C) culturing the multicellular cluster on a cellulose sponge; (D) exposing the cultured multicellular cluster to the medication or the treatment regimen; and (E) measuring a first survival rate of the cancer cell before exposing to the medication or the treatment regimen and a second survival rate of the cancer cell after exposing to the medication or the treatment regimen, when the second survival rate is lower than the first survival rate, the method predicts positive effect of the medication or the treatment regimen to the subject.

Abstract: A cytotoxicity method for medical devices that has equivalent sensitivity, and greater efficiency compared to the colony formation assay (CFA) direct contact method is developed. The quantitative, direct contact cytotoxicity test method uses Mouse lymphoma TK or human lymphoblastoid TK6 suspension cells for medical device safety assessment. The advantages of using the suspension cell assay over adherent V79-4 cells is that this approach is quantitative, automated, not susceptible to potential mechanical damage imparted by the overlying test materials, and avoids issues related to non-adherence of cells to the test material which might impact the interpretation of test results.

Abstract: The present invention provides a therapeutic and/or prophylactic medicament for FGFR3 diseases, the medicament comprising a HMG-CoA reductase inhibitor as an active ingredient; a method for treating and/or preventing FGFR3 diseases, the method comprising administering a HMG-CoA reductase inhibitor; use of a HMG-CoA reductase inhibitor in the production of a therapeutic and/or prophylactic medicament for FGFR3 diseases; and a method for screening for a therapeutic and/or prophylactic drug for FGFR3 diseases.

Abstract: Disclosed herein is a low cost and rapid microfluidic based method and test device for quantifying male fertility potential. The device can simultaneously measure three critical semen parameters rapidly, namely live sperm concentration, motile sperm concentration, and sperm motility. The device includes a transparent substrate and a top sheet with two holes therethrough and an intermediate sheet sandwiched between the substrate and the top sheet. The wells formed by holes form a concentration measuring well (C) and a motility well (M) formed by the top sheet with these two holes bonded to the intermediate sheet. A colorimetric agent is located on the top surface of the intermediate sheet at the bottom of each well which changes color when in contact with sperm. In the motility well a porous membrane is located on top of the colorimetric agent and a liquid buffer may be placed on the top surface of the porous membrane.

Abstract: The use of advanced flow cytometry for monitoring allergy sensitivity is mediated by the analysis of the cell mediated immune responses displayed by specialized white blood cells in response to specific allergens.

Abstract: The present invention relates to a kit for the detection of urease and to a tool and a composition forming part of the kit. In particular, the present invention relates to a kit for the detection of urease which comprises a composition containing an indicator; a delivery tool arranged to deliver a tissue sample into contact with the composition; and urea carried on the delivery tool, whereby the urea is arranged to be delivered to the composition together with the tissue sample.

Abstract: A method of determining the specific binding of ligand reversibly binding to a binding site in a sample using displacement competitive inhibition. The method comprising incubating the ligand (unlabeled) in the absence of a labeled ligand on a first tissue specimen, incubating the ligand (unlabeled) in the presence of a labeled ligand on a second tissue specimen, the first and the second tissue specimens being adjacent sections of specimen. MALDI imaging mass spectrometry is used to subsequently visualizing bound ligand localization, using in the first and second tissue specimen, respectively.

Abstract: Disclosed is an immunoassay method for detecting an analyte such as an antigen or an antibody in an isolated sample suspected to contain the analyte by incubating the sample with a plurality of binding partners, one of which carries a detectable label, wherein a label-specific binding partner is added that does not carry a label but binds to the detectable label. The method is applicable for a large variety of analytes and has proven particularly useful for analyte antibodies of the IgG and IgM class present in samples due to infections by pathogens. Also disclosed is a reagent kit useful for the method comprising at least two analyte-specific binding partners one of which carries a detectable label and a label-specific binding partner that binds to said detectable label but itself does not carry a detectable label.

Abstract: Provided is a method for detecting a test substance, the method including the steps of: forming an immune complex on a first solid phase by bringing a test substance, a labeled antibody, a capture antibody and the first solid phase into contact with one another; transferring the immune complex onto a second solid phase by breaking the binding between the capture antibody and the first solid phase to liberate the immune complex, and bringing the second solid phase and the immune complex into contact with each other, where the second solid phase is bound to the capture antibody; and detecting the test substance by measuring a label contained in the complex on the second solid phase. The test substance detected by the method is a multimeric antigen, particularly amyloid ? or tau protein.

Abstract: Additive techniques, including a direct-dilution method and a direct-incubation method, are described for isolating target entities in a fluid sample. In some implementations, a volume of a diluent is added to a fluid sample to generate a first mixture. The volume of the diluent added may be sufficient to obtain a specified viscosity of the first mixture lower than a viscosity of the fluid sample. A number of binding moiety-conjugated magnetic beads are added to the first mixture to generate a second mixture. The second mixture is incubated for a time that is sufficient for the binding moiety-conjugated magnetic beads to bind to rare target entities in the second mixture. A portion of the second mixture is injected into a fluidic chamber. A magnetic force is applied to attract the magnetized rare target entities in the second mixture to an isolation surface within the fluidic chamber.

Abstract: The present application provides compositions for multiplexed imaging using labeled nucleic acid imaging agents.

Abstract: The present disclosure relates to systems and methods for determination of analyte concentrations in solution using materials that are pre-dispensed and dried on conjugate pads or other solid substrates. The solution including the analyte can reconstitute the dried material within a vial to produce a specified concentration of material in the vial. The resulting solution can be used in lateral flow testing.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting autoimmune disease (e.g., multiple sclerosis and juvenile idiopathic arthritis), and risk of autoimmune disease, in a subject based on the levels of CD318.

Abstract: The present invention relates to methods of diagnosing lupus in a patient, as well as methods of monitoring the progression of lupus and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Abstract: In some embodiments, an immunoassay device for detection of recent malaria infection includes: a sample pad positioned adjacent to a first end of a conjugate pad, wherein either the sample pad or the first end of the conjugate pad include a detection complex able to bind anti-ETRAMP5 antibodies; wherein a second end of the conjugate pad includes one or more areas impregnated with a construct protein including ETRAMP5 protein fragments. In some embodiments, the detection complex for anti-ETRAMP5 antibodies includes a capture particle complexed with anti-IgG antibodies. In some embodiments, the detection complex for anti-ETRAMP5 antibodies includes a detection particle complexed with a complex molecule including ETRAMP5 protein fragments.

Abstract: The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). AITA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The invention encompasses combination therapies where knockdown of ATIA is used in combination with other treatment. The invention also features kits for use in the diagnostic and therapeutic methods.

Abstract: The purpose of the present invention is to provide an aptamer to a cancer cell, said aptamer being superior to conventional aptamers in binding ability, specificity, and/or stability. To solve this problem, provided is a DNA aptamer binding to a cancer cell, said DNA aptamer containing an artificial base(s).

Abstract: Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRPIO, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A 1 AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.

Abstract: A method of treating a subject, in particular a human, suffering from non-small cell lung cancer includes administering a bufadienolide to the subject. A method of inhibiting the proliferation and inducing the cell death of non-small cell lung cancer cells, a method of inhibiting the Epidermal growth factor receptor (EGFR) kinase activity in non-small cell lung cancer cells harboring an abnormality in the EGFR gene, and a method of inhibiting Na+/K+-ATPase in non-small cell lung cancer cells includes contacting those cells with a bufadienolide. Proscillaridin A as bufadienolide, with the structure of Formula (III) has advantageously high cytotoxicity against EGFR-dependent non-small cell lung cancer at nano-molar levels while having low toxicity to normal lung cells.

Abstract: Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for ?-N-acetylgalactosamine residue, such as Wisteria floribunda lectin, soybean agglutinin, Vicia Villosa lectin or an anti-?-N-acetylgalactosamine antibody, to the prostate-specific antigen.

Abstract: The present disclosure relates to a method for treating biliary tract cancer in a subject by inhibiting tenascin W by administering to said subject a therapeutically effective amount of a modulator of said tenascin, for example a specific antibody or a siRNA. The present disclosure also encompasses methods of diagnosing cancer by measuring levels of tenascin-W, as well as method of targeted therapy using anti-tenascin-W antibodies conjugated to therapeutic agents.

Abstract: The present invention relates to markers for diagnosing the difference in effects of renal cancer treatment or the prognosis of renal cancer patients, according to the gender of renal cancer patients. The survival rate and recurrence rate of renal cancer of a particular gender respectively relate to the mutation of genes, of the present invention, in renal cancer patients, and thus the mutated genes of the present invention can be used as markers in predicting, on the basis of gender, the difference in effects of renal cancer treatment or the prognosis of renal cancer patients.

Abstract: Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject, and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.

Abstract: The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.

Abstract: Provided is a method by which the quantity of objects to be detected can be quickly determined with high sensitivity. The method of determining the quantity of objects to be detected in a specimen comprises: a mixing step for preparing a mixture by mixing the specimen and carrier particles that carry stimulus-responsive substances and a first affinity substance for the objects to be detected; a measurement step for placing the mixture under the condition that the stimulus-responsive substances aggregate, and measuring the particle diameter of a suspended solid in the mixture; and a determination step for determining, on the basis of the particle diameter, the quantity of the objects to be detected.

Abstract: Disclosed is a citrate detection sensor including a compound represented by the Chemical Formula 1. The citrate detection sensor is bound specifically with citrate which is under-expressed specifically in cells, such as prostate cancer cells, to express a green fluorescence color. Thus, it is possible to detect citrate with ease by using the citrate detection sensor.

Abstract: According to the present teachings, compositions, kits, and methods for protein melt analysis are provided that utilizing one or more fluorophore dyes. In some embodiments, a method comprises preparing a sample by mixing at least one protein with two or more dyes, and applying a controlled heating, while recording the fluorescence emission of the sample. The methods can be used, for example, for screening conditions for optimized protein stability, screening for ligands that bind and enhance protein stability (e.g., protein-protein interactions), screening for mutations for enhanced stability, screening crystallization conditions for protein stability, screening storage conditions for protein stability, and screening conditions in which a protein will be used (e.g., production conditions, treatment conditions, etc.) for protein stability.

Abstract: The invention relates to a novel ligand inducible polypeptide coupling system and methods of modulating cell signal transduction pathways and other intracellular and extracellular protein-protein interactions.